So You've Written Academic Grants Before. Biotech Grants Are a Different Animal.
But don’t worry, your academic training still comes in handy.
Academic grant writing is a real skill.
If you've done it, you know how to build a literature review, construct a hypothesis, justify your aims, and write to a study section. That experience is not worthless in the biotech world. But if you walk into an SBIR application expecting it to feel like an R01, you are going to be confused, then frustrated, then possibly staring at a competitive score wondering what happened.
The science is the same. The game is different.
Reviewers Are Asking a Different Question
In academic grant writing, the central question reviewers are asking is: Is this good science? Is the hypothesis sound? Is the approach rigorous? Is the team credible? Does this advance the field? Those things matter in biotech grants too. But they are not the whole question.
In an SBIR or STTR application, reviewers are also asking: Will this become something? Is there a real market? Can this team actually execute a path from bench to product? Does this company have what it takes to survive long enough to commercialize? A brilliant scientific approach with no credible commercialization story will score worse than slightly less elegant science with a clear, believable path to market. That is a genuine culture shock for researchers coming from academia.
The Commercialization Plan Is Not an Afterthought
In academic grants, the broader impacts or significance section is often treated as a necessary formality. You write something thoughtful about how your work will advance the field, maybe mention training opportunities, and move on. The science is the main event.
In SBIR and STTR applications, the commercialization plan is a scored section. Reviewers read it carefully. They want to know who your customers are, what the competitive landscape looks like, how you'll get from your Phase I results to a product someone will pay for, and whether you've actually thought about a regulatory pathway. Vague language about "broad commercial potential" will not cut it. If you haven't done the market research, it shows immediately.
Your Preliminary Data Has a Different Job
In an academic grant, preliminary data exist to demonstrate scientific feasibility. It shows that your hypothesis is plausible and that your team can execute the approach. In a biotech grant, preliminary data needs to do that and more. It also needs to suggest that the technology works well enough to be worth the investment of federal dollars toward commercial development. The bar is not just "this is scientifically interesting." It's "this could actually work in the real world, and here's early evidence."
The Budget Tells a Story
Academic grant budgets are mostly about personnel, equipment, and supplies. Reviewers are checking that the math adds up and that the resources requested are proportionate to the work. In SBIR applications, the budget is scrutinized differently. Program officers and reviewers understand that a startup's costs look different from a university lab's, but they're also looking for signs that you understand what it actually costs to move something toward commercialization. Consultants, regulatory advisors, manufacturing feasibility studies: these are legitimate line items in a biotech grant budget that would look strange in an R01.
The Team Section Works Differently
Academic grants live and die on the PI's publication record and grant history. In biotech grants, the team evaluation is broader. Yes, scientific credentials matter. But reviewers are also looking for business acumen, regulatory experience, and evidence that someone on the team has done something like this before. If your founding team is all scientists with no operational or commercial experience, that's worth addressing directly rather than hoping reviewers don't notice.
What Carries Over
None of this means your academic grant writing skills are obsolete. The ability to write clearly about complex science, structure a logical argument, and anticipate reviewer objections is genuinely valuable and not easy to learn. The researchers who make the transition most smoothly are the ones who recognize that the underlying craft is the same, but the audience has different priors and different questions.
Write like a scientist. Think like a founder. That's the combination that wins in this space.
And if you're making that transition and want a thought partner who speaks both languages, well, that's exactly what we're here for.
Need a thought partner who speaks both languages?
I help health and health-focused teams plan, fund, and launch projects that get results. Reach out to discuss how we can work together to expand your impact.
Comments